Overview

Committed to Bettering the Lives of People in Pain

Centrexion Therapeutics is a late clinical-stage biopharmaceutical company focused on becoming a leader in identifying, developing and commercializing novel, non-opioid and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain.

 

A Unique and Diversified Pipeline of Non-opioid Treatments for Chronic Pain

 

At Centrexion Therapeutics, we have a broad pipeline that reflects our mission to tackle the problem of chronic pain directly. We are focused on developing treatments that address new or emerging pharmacological targets and deliver them in ways that best alleviate particular types of chronic pain. Our drug candidates include: topical gel, joint or deeper tissue injection, spinal delivery and three separate oral therapies. We believe that our broad pipeline of non-opioid and non-addictive drug candidates is uniquely positioned to address the limitations of currently-available therapies by providing safe, effective and durable pain treatment solutions.

Combining Big Data Analytics, Translational Science and Novel Clinical Trial Strategies
We believe that the most effective way to treat chronic pain is through therapies that specifically target the origin of the pain signal.

Management Team

Our senior management team has over 135 years of collective experience in leadership positions at companies with substantial product development experience and understands the complexity of designing and executing clinical trials for developing pain therapies.

Jeffrey B. Kindler

Chief Executive Officer

James N. Campbell, M.D.

President, Chief Scientific Officer

Randall Stevens, M.D.

Chief Medical Officer

Mike Ward

Chief Financial Officer

Kimberly Guedes

Vice President, Clinical Operations

Jonathan Guerriero

Vice President, Global Program & Portfolio Management

Jonathan Walker

Vice President, Manufacturing & CMC

Board of Directors

Sol Barer, Ph.D.

Chairman

Jeffrey B. Kindler

Chief Executive Officer

James N. Campbell, M.D.

President, Chief Scientific Officer

Raghav Bhargava

Director

Dan Mendelson

Director

Joseph R. Swedish

Director

Shawn Tomasello

Director

Stella Xu, Ph.D.

Director

Sean Zhang, Ph.D.

Director

Arnie Oronsky, Ph.D.

Director

In Memoriam

Centrexion Therapeutics notes with great sadness the passing of one its leaders, founders, and board members, Dr. Arnold Oronsky.  We are indebted to his exceptional vision and leadership and his inspirational belief in people and ideas.

November 2020

Robert Dworkin, Ph.D.

Robert Dworkin, Ph.D., is a professor of anesthesiology, neurology, oncology and psychiatry, and director of the Anesthesiology Clinical Research Center at the University of Rochester School of Medicine and Dentistry. Robert’s research has been funded by the National Institute of Health, the Department of Defense and various pharmaceutical companies. In particular, with funding from the FDA, Robert is examining studies and other efforts to improve the efficacy of analgesic clinical trials with the support of ACTTION public-private partnership, in which he also serves as director. Additionally, Robert is the associate editor of Pain, on the editorial board for both the Journal of Pain and the Current Pain and Headache Reports, and is a professional advisory board member for the American Chronic Pain Association. He is also the recipient of numerous awards such as the Mitchell B. Max Award for Neuropathic Pain by the American Academy of Neurology, the John and Emma Bonica Public Service Award by the American Pain Society and the John J. Bonica Award of the Eastern Pain Association. Robert received his B.A. from the University of Pennsylvania and his Ph.D. from Harvard University.

Tony Yaksh, M.D. Ph.D.

Tony Yaksh, M.D., Ph.D. is a professor in anesthesiology and pharmacology at the University of California, San Diego, where he is also vice chairman for research in anesthesiology and co-director of the Pain and Symptom Management Core at the UCSD Regional Cancer Center. His lab has been noted for its achievements in being the first to publish data on the effects of spinal baclofen, conducting the preclinical evaluations of analgesic actions of conopeptides in support of the clinical development of Prialt and for providing the pivotal data lead-in to the IND for Depofoam morphine for epidural use. Tony is the recipient of numerous awards, including the American Society of Anesthesiologists Award for Excellence in Research, the Bonica Award from the International Association for the Study of Pain and most recently, the Lifetime Achievement Award from the North American Neuromodulation Society. Tony obtained his Ph.D. degree from Purdue University before serving in the United States Army, working in the biomedical laboratory at Edgewood Arsenal.

Nathaniel Katz, M.D., M.S.

Nathaniel Katz, M.D., M.S., is internationally recognized for his expertise in pain management, analgesic clinical trials, and investigations focusing on opioids and risk management. As president and founder of Analgesic Solutions, Nathaniel established the company with the mission of modernizing the design and conduct of pain clinical trials to advance the scientific quality of pain clinical research and to empower effective treatments for patients. Prior to founding Analgesic Solutions, Nathaniel was a staff neurologist in the Pain Management Center of Brigham & Women’s hospital where he also founded the Pain Trials Center, a clinical analgesic research unit. He also founded the Pain & Symptom Management Program at Dana-Farber Cancer Institute. In addition to having served on numerous scientific advisory boards, Nathaniel has served as chairman to the Advisory Committee of Anesthesia, Critical Care and Addition Products Division of the FDA, as well as to the National Initiative on Pain Control. He is currently an adjunct assistant professor of Anesthesia at Tufts University School of Medicine and an active member of IMMPACT (Initiative on Methods, Measurements, and Pain Assessment in Clinical Trials). Nathaniel completed his neurology residency at Tufts New England Medical Center and later entered a pain management fellowship in the Department of Anesthesia at Brigham & Women’s Hospital. He received his medical degree from the Medical College of Pennsylvania and his M.S. in biostatistics from Columbia University.

Steve Cohen, M.D.

Steven Cohen, M.D., is a professor of anesthesiology and critical care medicine, and the director of the Blaustein Pain Treatment Center, Medical Education and Quality Improvement Pain Management Division at Johns Hopkins. He also acts as director of pain research at Walter Reed National Military Medical Center. Steven’s major contributions to pain research include the development of an FDA approved technique for treating sacroiliac joint pain (lateral branch radiofrequency denervation), inventing the intravenous ketamine test to help guide treatment in patients with chronic pain and performing the first studies evaluating the epidural administration of biological agents for pain. In 2014, Steven was listed as one of the top 10 experts in the world for back pain based on quantitative analysis of publications. In addition to his academic work, Steven is a retired Colonel in the U.S. Army. He serves as the Reserve Liaison to the Pain Management Consultants to the U.S. Army and Navy Surgeons General, and previously served as an inaugural member of the U.S. Army Medical Advisory Board. His research was instrumental in the passing of the Military Pain Care Act of 2008. Steven received his medical degree at the Mount Sinai School of Medicine, completed an anesthesiology residency at Columbia University and a pain management fellowship at Massachusetts General Hospital.

Duncan Lascelles, BVSc, Ph.D.

Duncan Lascelles, BVCs, Ph.D., is a professor of small animal surgery, director of integrated pain management service, director of the Comparative Pain Research Laboratory and the associate director of the Center for Comparative Medicine and Translational Research at North Carolina State University. His research is focused on developing algometry methods in spontaneous disease animal models and probing tissues from well-phenotyped animals to better understand the neurobiology. The aim of such research is to improve pain control in companion animals and facilitate analgesic development in human medicine. Dr. Lascelles is board certified in small animal surgery by the Royal College of Veterinary Surgeons, the European College of Veterinary Surgeons and the American College of Veterinary Surgeons. Dr. Lascelles completed a Ph.D. in aspects of pre-emptive/perioperative analgesic at the University of Bristol, U.K., after graduating from their veterinary program. He went on to complete his surgical residency at the University of Cambridge, U.K., followed by a fellowship in oncological surgery at Colorado State University.

Philip Conaghan, MBBS, Ph.D., FRACP, FRCP

Professor Philip Conaghan MBBS PhD FRACP FRCP is Professor of Musculoskeletal Medicine & Director of the Leeds Institute of Rheumatic and Musculoskeletal Medicine at the University of Leeds. He is a Rheumatologist and Deputy Director of the UK National Institute for Health Research Leeds Biomedical Research Centre for the Leeds Teaching Hospitals NHS Trust. He is also Director of an Arthritis Research UK Experimental Osteoarthritis Treatment Centre in Leeds. His research spans early translational studies through large late-phase clinical trials, with major interests in understanding pathogenesis and therapeutic response for common arthritides, especially osteoarthritis. He is an executive member of the international outcomes group OMERACT, was inaugural Chair of the EULAR Standing Committee on Musculoskeletal Imaging and was Chair of UK NICE OA clinical guidance in 2008 and 2014. He is on a number of editorial boards, is co-editor of the most recent Oxford Textbook of Rheumatology and has authored over 500 publications as original research, reviews and book chapters.

Sol Barer, Ph.D.

Chairman

Sol Barer, Ph.D. is a founder and chairman of the board of directors of Centrexion Therapeutics. Sol brings more than 30 years of experience in the biotechnology industry. He is the managing partner of SJBarer Consulting and was a founder of Celgene, a global biopharmaceutical company. From 1987 to 2011, Sol led Celgene in various executive roles, including president, COO and CEO. He also served as the executive chairman and chairman of the company’s board of directors. Sol currently serves as chairman of the board of Teva Pharmaceutricals, Edge Therapeutics, Inc. and Aevi Genomic Medicine. He is also lead director of Contrafect Corp. He is also the Founding Chair of the Hackensack Meridian Health Center for Discovery & Innovation and is associated with Barer & Son LLC which invests in early stage breakthrough biotechnology companies. Sol holds a B.S. from Brooklyn College and a Ph.D. in organic chemistry from Rutgers University.

Jeffrey B. Kindler

Chief Executive Officer

Jeff Kindler joined Centrexion Therapeutics as the chief executive officer in 2013. He brings more than three decades of business experience and has held leadership positions at some of the world’s most recognized companies. Jeff is also executive chair of vTv Therapeutics, venture partner at Lux Capital, managing director at Starboard Capital and the global chair for the GLG Institute. Prior to joining Centrexion, Jeff was the chairman and CEO of Pfizer, the world’s largest research-based biopharmaceutical company. As CEO, he led Pfizer’s $68 billion merger and acquisition of Wyeth, diversified its product portfolio, improved its research and development pipeline, and reshaped the company’s commercial, innovation and leadership models to drive growth and cultural change. Earlier in his career, Jeff served as the executive vice president and general counsel for McDonald’s Corporation and was the vice president of litigation and legal policy for the General Electric Company. Prior to GE, Jeff practiced civil and criminal litigation as a Partner of William & Connolly. Jeff holds a B.A. from Tufts University and a J.D. from Harvard University.

James N. Campbell, M.D.

President, Chief Scientific Officer

James Campbell, M.D. is a founder, president and chief scientific officer of Centrexion Therapeutics. Jim is Professor Emeritus of neurosurgery at Johns Hopkins University School of Medicine. He has published over 100 peer-reviewed scientific studies in the field of pain research, which have been recognized through many national honors. In 1996, Jim was president of the American Pain Society. Prior to joining Centrexion, he served as the CEO of Arcion Therapeutics, a biotech company developing topical products for the treatment of neuropathic pain. Earlier in his career, he served as the CEO for Vallinex, Inc. He served as the founder of the American Pain Foundation and was chairman of the board for ten years. He also served as board observer and co-founder of CNS Therapeutics, and was co-founder and on the board of directors of Amplimmune. Jim holds a B.A. in psychology with high honors and high distinction from the University of Michigan, and received his M.D. from Yale University. He received his training in Neurosurgery at the Johns Hopkins Hospital, and is a Diplomate of the American Board of Neurological Surgery.

Randall Stevens, M.D.

Chief Medical Officer

Randall Stevens, M.D. joined Centrexion Therapeutics as the chief medical officer in April 2015. Randall is a board-certified internist and rheumatologist with more than 25 years of experience in pharmaceutical medicine. Prior to joining Centrexion, he served as the corporate vice president, head of inflammation and immunology clinical development for Celgene Corporation. Earlier in his career, Randall spent 11 years at F. Hoffmann La Roche where he was a global leader in inflammation and immunology clinical research. In total, Randall has played an integral role in bringing five drugs to market. Additionally, he has been a clinical professor of medicine at Robert Wood Johnson School of Medicine since 1990 and a board member for Outcome Measures Rheumatic Clinical Trails (OMERACT) since 2007. Randall has authored or co-authored more than 40 peer-reviewed publications. He holds a B.A. in chemistry and Spanish, and a M.D. from Case Western Reserve University School of Medicine.

Mike Ward

Chief Financial Officer

Mike Ward joined Centrexion Therapeutics as CFO in 2019. He brings more than 25 years of experience, predominantly as an investment banker focused on life sciences and as both CFO and CBO of public and private life sciences companies. Prior to joining Centrexion, Mike served as CFO and CBO of Bionano Genomics, a NASDAQ-listed life sciences company. Prior to Bionano Genomics, Mike served as Executive Director of the Private Equity team of Lurie Investment Fund with a focus on life sciences investments. As an investment banker, Mike completed over 100 life sciences financings and M&A transactions (including nearly 20 IPOs) at Leerink Partners, Credit Suisse, BMO, Wasserstein and Prudential Securities. Mike has also served on the board of directors of public and private life sciences companies, including Nanosphere, CytoPherx, Aperion Biologics and Impact Health. Mike graduated summa cum laude (highest distinction) from the University of Illinois in 1993 with a Bachelor of Science in Finance with a concentration in Accounting.

Kimberly Guedes

Vice President, Clinical Operations

Kimberly Guedes joined Centrexion Therapeutics as Senior Director of Clinical Operations in 2015 and quickly advanced to her current role as VP of Clinical Operations. Her entrepreneurial approach is informed by 25+ years in every area of drug development including pre-clinical, Phase I-IV, and translational research trials. From Research Coordinator at Yale University School of Medicine to Senior Director of Global Clinical Operations at pharmaceutical and biotech companies  and CROs including Merck Pharmaceuticals, Mitsubishi Pharm, QED Pharmaceutical Services, and Clinsys Clinical Research, Kim has established herself as a subject matter expert in clinical development and operations and complex global regulatory issues (GDPR) . Her leadership and engaging interpersonal style have delivered multimillion-dollar bids with pharmaceutical companies,  global research studies launched in the US, EU, South America, and PAC-Asia, as well as multiple, sequential, phase III trials achieved ahead of schedule, and within budget.

Kim is a regular presenter at professional conferences and was recognized at the MAGI Clinical Research Conference as a top speaker. She holds a BSN/RN, is currently pursuing her MBA at the University of Dayton, and was recently awarded the Carolyn E. Green Scholarship dedicated to leadership opportunities for women in the life sciences industry.

Jonathan Guerriero

Vice President, Global Program & Portfolio Management

Jonathan joined Centrexion in June 2019 bringing two decades of leadership, program development and clinical operations experience in the pharmaceutical and biotech industry. Jonathan has held positions of increasing responsibility leading development programs in early phase through post-approval, starting up and managing clinical operations functions, and working in clinical development. Prior to joining Centrexion, Jonathan served as the Executive Director of Clinical Operations at Akcea Therapeutics where he was responsible for building an infrastructure and managing multiple drug development program clinical trials through registration. Before Akcea, Jonathan held positions at Synageva, Radius Health, and EMD Serono. Jonathan also has been appointed a Visiting Scholar at Boston College’s Connell School of Nursing where he has been teaching clinical research programs since 2006.

Jonathan Walker

Vice President, Manufacturing & CMC

Jonathan Walker is the Vice President of Manufacturing and CMC at Centrexion Therpautics. After receiving both his BA and DPhil in Chemistry from the University of Oxford, Jonathan Walker began his career at Syntex Chemicals, Inc. before joining Parke-Davis Warner-Lambert and then Bristol-Myers Squibb. Most recently, he was Vice President of Manufacturing at Tetraphase Pharmaceuticals and Senior Director of Commercial Manufacturing at Ironwood Pharmaceuticals prior to that. He has over thirty years of experience in all aspects of laboratory process research and development, pilot plant scale-up and commercial manufacturing of active pharmaceutical ingredients, drug products and finished goods. He currently is responsible for the supply of drug products from Contract Manufacturing Organizations to support Centrexion’s novel non-opiod pain management programs.

Arnie Oronsky, Ph.D.

Director

Arnie Oronsky, Ph.D. was a founder and board member of Centrexion Therapeutics. Arnie served as a general partner and managing director at InterWest Partners LLC, a venture capital firm. Earlier in his career, Arnie led pharmaceutical research as vice president for discovery research for the Lederle Laboratories division of American Cyanamid Company. He was a board member of Applied Genetic Technologies Corporation, Drais Pharmaceuticals, Dynavax Technologies, EpicentRx, Integrated Diagnostics, PMV Pharma, Potenza Therapeutics, Sera Prognostics, TESARO and Tizona Therapeutics. Arnie held a B.A. degree from New York University, a Ph.D. in Immunology from Columbia University and was a senior lecturer at Johns Hopkins Medical School.

Raghav Bhargava

Director

Raghav joined NEA in 2018, and is currently a member of the biopharma investing team. Prior to joining NEA, Raghav was a member of Lazard’s healthcare M&A group in New York. At Lazard, Raghav worked with clients across the life sciences, medical device, and healthcare services sectors.

Raghav graduated from the Roy and Diana Vagelos Program at the University of Pennsylvania, where he earned a B.A. in Biology from the College of Arts and Sciences and a B.S. in Economics from the Wharton School. During his time at the University of Pennsylvania, Raghav conducted both laboratory research and advisory work related to engineered T cell therapy for oncology.

Dan Mendelson

Director

Dan Mendelson joined the Centrexion Therapeutics board of directors in August 2018 with substantial healthcare expertise and leadership. Currently, Dan is advisor of Avalere Health, a group which he founded in 2000 and grew organically as chief executive officer until 2015, when he sold the company to Inovalon Holdings (INOV). Prior to that, he served as associate director for health at the Office of Management and Budget where he oversaw numerous government healthcare programs and agencies, as well as the development of numerous initiatives in health information technology and medical error prevention, the electronic disease surveillance system, and policies in reimbursement and technology assessment. Dan presently serves on the board of Champions Oncology, as well as on the advisory boards for Faster Cures, the Alliance for Health Policy and the Duke Margolis Center. In addition, he is a founding member of Guidon Partners, an investment management group, and is executive in residence at the Fuqua School of Business at Duke University. Dan received his undergraduate degree in economics and viola performance from Oberlin College and his master’s degree in public policy from the Kennedy School of Government at Harvard University.

Joseph R. Swedish

Director

Mr. Swedish joined the Centrexion Therapeutics board of directors in June 2018 with significant experience in healthcare leadership. He is a Co-Founder and Partner at Concord Health Partners and a member of the Firm’s Investment Committee. Mr. Swedish has more than 45 years of healthcare leadership experience. Most recently, Mr. Swedish was Chairman, President & Chief Executive Officer of Anthem, Inc., a Fortune 29 company and the nation’s leading health benefits provider. He also served for more than 25 years as CEO for several major health systems, most recently Trinity Health, a 22-state integrated health care delivery system. Previously, he was President & CEO of Centura Health, Colorado’s largest health system, and formerly served as Division President for Hospital Corporation of America. Mr. Swedish has been extensively recognized for his leadership in the healthcare field. For 12 years in a row, Modern Healthcare named him one of the 100 Most Influential People in Healthcare, ranking in the top 20 of the health sector’s most senior-level executives, high-level government administrators, elected officials, academics, and thoughts-leaders for five consecutive years. In 2016, Mr. Swedish was one of five health care leaders named to Crain Communications’ Top 100 Innovators list. Mr. Swedish’s commitment to education, public service, diversity and inclusion, and better health care for all extends to his numerous board affiliations. He serves on the board of directors for IBM Corporation, CDW, Mesoblast Limited (chairman) and Centrexion Therapeutics. Also, he has served as chairman and is currently a member of Duke University’s Fuqua School of Business Board of Visitors. Previously, Mr. Swedish served as board chairman of America’s Health Insurance Plans (AHIP), and chairman of the board, Catholic Health Association, a 600-hospital member organization. He has also held board and advisory positions with American Hospital Association (AHA), Coventry Health Care, Inc., RehabCare Group, Inc., BankFIRST, Cross Country, Inc., National Quality Forum, American Hospital Association’s (AHA) Institute for Diversity in Healthcare Management, and Loyola University Chicago. Mr. Swedish received his bachelor’s degree from the University of North Carolina at Charlotte and his master’s (MHA) degree in health administration from Duke University.

Shawn Tomasello

Director

Shawn Tomasello joined the Centrexion Therapeutics board of directors in 2017. With over 30 years of experience in the pharmaceutical and biotech industries, Shawn currently serves as chief commercial officer of Kite Pharma. Prior to her role at Kite Pharma, Shawn served as chief commercial officer at Pharmacyclics, Inc., preceding its acquisition by AbbVie, Inc. She also held various senior leadership roles at Celgene Corporation, including president of the Americas, hematology and oncology. Earlier in her career, Shawn held positions at Genentech, Pfizer Laboratories, Miles Pharmaceuticals and Procter & Gamble. She currently serves on the board of Oxford BioTherapeutics and Diplomat Rx. Shawn received her B.S. in marketing from the University of Cincinnati and her MBA from Murray State University.

Stella Xu, Ph.D.

Director

Dr. Stella Xu joined the Centrexion Therapeutics board of directors in 2018 with over 20 years of experience in the biopharmaceutical industry. She is a managing director of Quan Capital, a life sciences venture fund with offices in China & the United States, and has deep expertise in cross board value creation and global investments. Prior to Quan, Stella was vice president and site head of Roche Innovation Center Shanghai, and a core member of the global management team for Roche’s Immunology, Inflammation & Infectious Diseases Discovery and Translation Area. She led the integrated research and early development site in China to discover and develop innovative medicines for global patients. Stella also established the Roche Partnering office in Shanghai and managed business development and licensing activities in APAC (ex-Japan) from 2008 to 2012. Prior to her leadership roles in Asia, she managed global due diligence transaction activities and key alliances across disease areas in Roche Partnering US. Stella joined Roche from McKinsey where she led consulting engagements with healthcare clients in diverse functional areas. Earlier in her career, Stella worked in biotech drug discovery in oncology & inflammation. Stella received her Ph.D. in Immunology from Northwestern University, and her B.S. in Biophysics from Peking University.

Sean Zhang, Ph.D.

Director

Sean Zhang, Ph.D. is a Vice President at Lilly Asia Ventures (LAV). Prior to joining LAV, he was a management consultant at McKinsey’s Silicon Valley office, focused on strategic consulting for biotech, pharma and medtech companies. Prior to McKinsey, Sean worked in business development and research at Allele biotech in San Diego. Sean completed his Postdoc research at UC San Diego in neuroscience and ophthalmology, and he holds Ph.D. in molecular biology from the University of Pittsburgh School of Medicine and B.S. in Bioengineering from Xi’an Jiaotong University.